RepliCel Ships DermaPrecise(TM) Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing November 11, 2021
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team November 9, 2021
Looking for your next +30% opportunity? Join our multi-sector high growth stock virtual event October 27, 2021 Cannabis, Consumer Goods, Life Science, Technology
Hemostemix Confirms OTCQB Application is Filed October 19, 2021 Cannabis, Consumer Goods, Life Science, Technology
RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy October 18, 2021 Cannabis, Consumer Goods, Life Science, Technology
Hemostemix Announces Dr. Fraser C. Henderson Sr., MD, as Chief Medical Officer October 14, 2021 Cannabis, Consumer Goods, Life Science, Technology
RepliCel Life Sciences Appoints One of Japan’s Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor October 12, 2021 Cannabis, Consumer Goods, Life Science, Technology
Hemostemix Announces the Second Stem Cell Recipient Interview: One Week to No Chest Pain October 4, 2021 Cannabis, Consumer Goods, Life Science, Technology
Insights into China’s Pharmaceutical Industry Trends from a 2,000-strong Industry Conference September 30, 2021 Life Science
Hemostemix Announces Closing of First Tranche of Unit Private Placement September 21, 2021 Life Science
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents September 16, 2021 Life Science
Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years September 14, 2021 Life Science
